TNFRSF1B and type 1 diabetes mellitus: In particular, TNFR2 was shown to selectively promote death of autoreactive T cells in human diabetes (Ban et al., 2008; Okubo et al., 2016) and promoting Treg activity is a promising approach to treat type I diabetes (Visperas and Vignali, 2016).